News Releases

ACZONE® (dapsone) GEL, 7.5% Now Approved For The Topical Treatment Of Acne Vulgaris In Patients 9 Years Of Age And Older

Almirall issues call for grant submissions for development of new immunodermatology therapies through AlmirallShare

Almirall Partners with AARS to Raise Awareness about the Burden of Disease and Importance of Education for Dermatology Professionals for National Acne Awareness Month

Almirall Q1 2019. Strong operating performance

Almirall Recognized As Distinguished Corporate Leader By American Skin Association - Unveiled Patient-Driven Purpose

Almirall and Athenex Announce Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting

Almirall enters into a definitive agreement to divest ThermiGen, its medical device aesthetics business

Novel Oral Antibiotic SEYSARA™ (sarecycline) Now Available

Almirall LLC Launches New Name at Fall Clinical Dermatology Congress

Almirall acquires Allergan U.S. medical dermatology portfolio